Abramson Cancer Center at Penn Medicine
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Viral Vaccines
Influenza vaccination
SARS-CoV-2 vaccine
Zoster Vaccine Recombinant
Vaccinations are indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. In particular, immune responses following vaccination have not been studied in the setting of cancer and in the context of various anti-tumor treatments. In this study, the investigators will look at the immune response of subjects receiving vaccination.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 250 participants |
| Official Title : | Vaccine Responses in Cancer |
| Actual Study Start Date : | 2022-11-04 |
| Estimated Primary Completion Date : | 2027-10 |
| Estimated Study Completion Date : | 2028-10 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104